Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China flag China · Delayed Price · Currency is CNY
39.89
+0.88 (2.26%)
Apr 28, 2026, 3:00 PM CST
34.04%
Market Cap 27.05B
Revenue (ttm) 4.92B
Net Income (ttm) 2.13B
Shares Out 770.09M
EPS (ttm) 2.77
PE Ratio 14.40
Forward PE 27.32
Dividend 4.68 (12.00%)
Ex-Dividend Date Feb 12, 2026
Volume 3,361,550
Average Volume 3,446,324
Open 39.00
Previous Close 39.01
Day's Range 38.92 - 39.89
52-Week Range 29.19 - 50.97
Beta 0.74
RSI 41.39
Earnings Date Mar 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Sector Healthcare
Founded 1915
Employees 3,890
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600329
Full Company Profile

Financial Performance

In 2025, SHA:600329's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial Statements

News

There is no news available yet.